Eli Lilly and Company (LLY) 77.01 $LLY
Amazon, Microsoft, McDonald's, Under Armour Earnings in Focus
at The Street - Wed Oct 21, 7:15PM CDT
Alphabet, Union Pacific and Southwest Airlines are among the many companies reporting earnings Thursday.
MMM: 149.82 (+0.71), AMZN: 555.77 (-5.11), LLY: 77.01 (-0.78), GOOG: 642.61 (-7.67), LUV: 41.04 (-0.34), UAL: 54.55 (-1.20), T: 33.60 (-0.15), UA: 99.15 (-0.82), MCD: 102.54 (-1.30), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), DOW: 47.48 (-0.21), UNP: 93.41 (-0.33)
Biotech Stocks Slump Again on Valeant's 'Smoking Gun'
at The Street - Wed Oct 21, 3:02PM CDT
Biotech stocks were in the crossfire again on Wednesday as investors fled. But this time Hillary Clinton wasn't to blame.
KO: 42.19 (-0.10), VRX: 118.61 (-28.13), F: 15.41 (+0.03), KMB: 118.09 (+0.87), PFE: 33.46 (-0.54), IBB: 304.46 (-1.50), FCAU: 15.20 (-0.74), LLY: 77.01 (-0.78), TM: 123.70 (+1.49), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), GM: 35.42 (+1.94), ABBV: 53.83 (-1.00), HMC: 32.70 (+0.70), RACE: 55.00 (-5.00)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 210.09 (-2.94), BIIB: 276.34 (+10.53), F: 15.41 (+0.03), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), TM: 123.70 (+1.49), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), HMC: 32.70 (+0.70), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), LLY: 77.01 (-0.78), FCAU: 15.20 (-0.74), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), LRCX: 70.79 (+0.76), MCD: 102.54 (-1.30), GM: 35.42 (+1.94), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Eli Lilly (LLY) Approaches New Downside Target of $75.87
Comtex SmarTrend(R) - Wed Oct 21, 1:03PM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $78.58 and have already reached the first level of support at $76.83. Investors may be interested in a cross of the next downside pivot targets of $75.87 and $73.16.
LLY: 77.01 (-0.78)
Global HER2-Negative Breast Cancer Market 2015-2019
M2 - Wed Oct 21, 10:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3b7bbx/global) has announced the addition of the "Global HER2-Negative Breast Cancer Market 2015-2019" report to their offering. The global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019. The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies. According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters. Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients. Based on type of drug molecule, the market is segmented as follows: - Biologics - Small molecules Based on route of administration, the market is segmented as follows: - Oral - Parenteral Key vendors - F. Hoffmann-La Roche - Novartis - Pfizer Other prominent vendors - AbbVie - AstraZeneca - BioMarin - Bristol-Myers Squibb - Eisai - Eli Lilly - Galena Biopharma - Incyte - Merck - Merck Serono - Merrimack - Nektar - Tesaro For more information visit http://www.researchandmarkets.com/research/3b7bbx/global
MRK: 50.59 (+0.20), GALE: 1.65 (-0.06), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38), NVS: 91.59 (-0.74)
After Yesterday's Decline of 3.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 77.01 (-0.78)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 3.07%
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 77.01 (-0.78)
Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
Business Wire - Tue Oct 20, 9:00AM CDT
Yabao Pharmaceutical Co., Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, today announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive pre-clinical development. In July 2014, Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.
LLY: 77.01 (-0.78)
Can Eli Lilly & Co. Recover From Expensive Failures?
Cory Renauer, The Motley Fool - Motley Fool - Tue Oct 20, 7:36AM CDT
On Monday, Eli Lilly announced an abrupt end to another large phase 3 clinical trial, just as things were beginning to look up for the beleaguered drugmaker. Recently posted data from its next-generation diabetes therapy made it seem like things...
LLY: 77.01 (-0.78)
Lilly's board to pay Q4 2015 dividend of USD0.50 per common share
M2 - Tue Oct 20, 4:49AM CDT
The board of directors of Eli Lilly and Company (NYSE:LLY) on Monday declared its dividend of USD0.50 per share on its outstanding common stock for the Q4 2015.
LLY: 77.01 (-0.78)
Is Lilly (LLY) Poised to Beat Earnings Expectations in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 3:26PM CDT
Will Lilly (LLY) succeed in surpassing earnings expectations on the back of strong diabetes and animal health segment sales?
AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), NVS: 91.59 (-0.74)
Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 1:50PM CDT
Abbott Laboratories (ABT) carrying a Zacks Rank #4 and an Earnings ESP of -1.83% is scheduled to report third-quarter 2015 results on Oct 21, 2015.
ABT: 42.20 (+0.46), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38)
Lilly Declares Fourth-Quarter 2015 Dividend
PR Newswire - Mon Oct 19, 1:31PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2015 of $0.50 per share on outstanding common stock.
LLY: 77.01 (-0.78)
Eli Lilly's Failure Is a Success for These Companies
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 19, 6:42AM CDT
Image source: Eli Lilly. The mothballing of Eli Lilly 's once-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor to Regeneron and Amgen 's recently launched cholesterol busters while also reducing...
ESPR: 22.51 (-0.29), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86)
PEP, KMB, STX, IBM: Jim Cramer's Views
at The Street - Mon Oct 19, 12:00AM CDT
Jim Cramer shares his views on the chicken growth stocks and intra-sector rotations. Pepsico, Kimberly-Clark, Seagate Technology and IBM are among the stocks discussed here.
MU: 16.43 (-0.66), AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), SWKS: 77.67 (-0.62), CLX: 122.06 (-0.02), STX: 37.13 (-1.39), KMB: 118.09 (+0.87), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), NXPI: 91.32 (-0.67), WDC: 71.44 (-3.42), INTC: 33.37 (-0.07), HPQ: 28.23 (-0.33), PEP: 100.25 (-0.02), CELG: 115.92 (-0.32), QRVO: 48.50 (+0.30), IBM: 140.92 (+0.28), KHC: 77.05 (+0.18), SNDK: 76.78 (+1.59), REGN: 518.53 (+3.86), AVGO: 120.50 (+0.61), CRM: 75.83 (-1.70)
Futures Flat; Investors Wary Ahead of China Data
at The Street - Sun Oct 18, 6:37PM CDT
China is expected to post its weakest quarterly economic growth since the global financial crisis.
KMI: 31.42 (-0.51), CCI: 83.13 (-0.04), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), AMT: 96.06 (-0.85), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), DBD: 35.06 (-0.97), AMZN: 555.77 (-5.11), FITB: 18.28 (-0.55), SBAC: 111.14 (-1.02), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38)
Futures Dip Slightly After China GDP Barely Beats
at The Street - Sun Oct 18, 9:42AM CDT
China posted its weakest quarterly economic growth since the global financial crisis.
KMI: 31.42 (-0.51), CCI: 83.13 (-0.04), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), AMT: 96.06 (-0.85), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), DBD: 35.06 (-0.97), AMZN: 555.77 (-5.11), FITB: 18.28 (-0.55), SBAC: 111.14 (-1.02), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38)
'Fast Money' Recap: China Could Have Big Role in US Rally's Future
at The Street - Sat Oct 17, 4:00AM CDT
The trading panel discussed their stock picks ahead of earnings and whether Steve Ballmer is doing the right thing investing in Twitter.
BIIB: 276.34 (+10.53), AMZN: 555.77 (-5.11), CMG: 665.67 (-39.96), MCD: 102.54 (-1.30), LLY: 77.01 (-0.78), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), TWTR: 29.30 (-1.61), MSFT: 47.20 (-0.57), BA: 141.19 (+2.31), YUM: 73.56 (+0.53)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 16, 7:13PM CDT
There are a slew of earnings reports expected next week. Cramer's advice? Stop, listen and learn.
KMI: 31.42 (-0.51), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), PEP: 100.25 (-0.02), NVGS: 14.06 (-0.85), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), VAC: 63.04 (-1.45), CMG: 665.67 (-39.96), NAT: 16.39 (+0.10), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), AMZN: 555.77 (-5.11), FEYE: 28.76 (-1.53), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38), EPD: 27.13 (-0.77)
IBM, Yahoo!, Chipotle and McDonald's Part of Heavy Earnings Slate
at The Street - Fri Oct 16, 5:19PM CDT
Also reporting this week are Verizon, United Technologies and General Motors, among many others.
KMI: 31.42 (-0.51), MMM: 149.82 (+0.71), LMT: 211.56 (+2.83), VMW: 55.42 (-13.34), UTX: 97.97 (+2.35), LVS: 46.84 (-0.48), YHOO: 31.12 (-1.71), T: 33.60 (-0.15), EBAY: 24.21 (-0.21), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), EMC: 25.77 (-1.72), SIX: 51.19 (+0.11), MSFT: 47.20 (-0.57), UNP: 93.41 (-0.33), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), AXP: 76.51 (-0.44), CS: 24.98 (-0.98), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), MS: 31.48 (-0.77), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38), DOW: 47.48 (-0.21)
Amazon, Microsoft, McDonald's, Under Armour Earnings in Focus
at The Street - Wed Oct 21, 7:15PM CDT
Alphabet, Union Pacific and Southwest Airlines are among the many companies reporting earnings Thursday.
MMM: 149.82 (+0.71), AMZN: 555.77 (-5.11), LLY: 77.01 (-0.78), GOOG: 642.61 (-7.67), LUV: 41.04 (-0.34), UAL: 54.55 (-1.20), T: 33.60 (-0.15), UA: 99.15 (-0.82), MCD: 102.54 (-1.30), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), DOW: 47.48 (-0.21), UNP: 93.41 (-0.33)
Biotech Stocks Slump Again on Valeant's 'Smoking Gun'
at The Street - Wed Oct 21, 3:02PM CDT
Biotech stocks were in the crossfire again on Wednesday as investors fled. But this time Hillary Clinton wasn't to blame.
KO: 42.19 (-0.10), VRX: 118.61 (-28.13), F: 15.41 (+0.03), KMB: 118.09 (+0.87), PFE: 33.46 (-0.54), IBB: 304.46 (-1.50), FCAU: 15.20 (-0.74), LLY: 77.01 (-0.78), TM: 123.70 (+1.49), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), GM: 35.42 (+1.94), ABBV: 53.83 (-1.00), HMC: 32.70 (+0.70), RACE: 55.00 (-5.00)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 210.09 (-2.94), BIIB: 276.34 (+10.53), F: 15.41 (+0.03), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), TM: 123.70 (+1.49), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), HMC: 32.70 (+0.70), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), LLY: 77.01 (-0.78), FCAU: 15.20 (-0.74), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), LRCX: 70.79 (+0.76), MCD: 102.54 (-1.30), GM: 35.42 (+1.94), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Eli Lilly (LLY) Approaches New Downside Target of $75.87
Comtex SmarTrend(R) - Wed Oct 21, 1:03PM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $78.58 and have already reached the first level of support at $76.83. Investors may be interested in a cross of the next downside pivot targets of $75.87 and $73.16.
LLY: 77.01 (-0.78)
Global HER2-Negative Breast Cancer Market 2015-2019
M2 - Wed Oct 21, 10:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3b7bbx/global) has announced the addition of the "Global HER2-Negative Breast Cancer Market 2015-2019" report to their offering. The global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019. The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies. According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters. Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients. Based on type of drug molecule, the market is segmented as follows: - Biologics - Small molecules Based on route of administration, the market is segmented as follows: - Oral - Parenteral Key vendors - F. Hoffmann-La Roche - Novartis - Pfizer Other prominent vendors - AbbVie - AstraZeneca - BioMarin - Bristol-Myers Squibb - Eisai - Eli Lilly - Galena Biopharma - Incyte - Merck - Merck Serono - Merrimack - Nektar - Tesaro For more information visit http://www.researchandmarkets.com/research/3b7bbx/global
MRK: 50.59 (+0.20), GALE: 1.65 (-0.06), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38), NVS: 91.59 (-0.74)
After Yesterday's Decline of 3.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 77.01 (-0.78)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 3.07%
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 77.01 (-0.78)
Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
Business Wire - Tue Oct 20, 9:00AM CDT
Yabao Pharmaceutical Co., Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, today announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive pre-clinical development. In July 2014, Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.
LLY: 77.01 (-0.78)
Can Eli Lilly & Co. Recover From Expensive Failures?
Cory Renauer, The Motley Fool - Motley Fool - Tue Oct 20, 7:36AM CDT
On Monday, Eli Lilly announced an abrupt end to another large phase 3 clinical trial, just as things were beginning to look up for the beleaguered drugmaker. Recently posted data from its next-generation diabetes therapy made it seem like things...
LLY: 77.01 (-0.78)
Lilly's board to pay Q4 2015 dividend of USD0.50 per common share
M2 - Tue Oct 20, 4:49AM CDT
The board of directors of Eli Lilly and Company (NYSE:LLY) on Monday declared its dividend of USD0.50 per share on its outstanding common stock for the Q4 2015.
LLY: 77.01 (-0.78)
Is Lilly (LLY) Poised to Beat Earnings Expectations in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 3:26PM CDT
Will Lilly (LLY) succeed in surpassing earnings expectations on the back of strong diabetes and animal health segment sales?
AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), NVS: 91.59 (-0.74)
Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 1:50PM CDT
Abbott Laboratories (ABT) carrying a Zacks Rank #4 and an Earnings ESP of -1.83% is scheduled to report third-quarter 2015 results on Oct 21, 2015.
ABT: 42.20 (+0.46), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38)
Lilly Declares Fourth-Quarter 2015 Dividend
PR Newswire - Mon Oct 19, 1:31PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2015 of $0.50 per share on outstanding common stock.
LLY: 77.01 (-0.78)
Eli Lilly's Failure Is a Success for These Companies
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 19, 6:42AM CDT
Image source: Eli Lilly. The mothballing of Eli Lilly 's once-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor to Regeneron and Amgen 's recently launched cholesterol busters while also reducing...
ESPR: 22.51 (-0.29), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86)
PEP, KMB, STX, IBM: Jim Cramer's Views
at The Street - Mon Oct 19, 12:00AM CDT
Jim Cramer shares his views on the chicken growth stocks and intra-sector rotations. Pepsico, Kimberly-Clark, Seagate Technology and IBM are among the stocks discussed here.
MU: 16.43 (-0.66), AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), SWKS: 77.67 (-0.62), CLX: 122.06 (-0.02), STX: 37.13 (-1.39), KMB: 118.09 (+0.87), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), NXPI: 91.32 (-0.67), WDC: 71.44 (-3.42), INTC: 33.37 (-0.07), HPQ: 28.23 (-0.33), PEP: 100.25 (-0.02), CELG: 115.92 (-0.32), QRVO: 48.50 (+0.30), IBM: 140.92 (+0.28), KHC: 77.05 (+0.18), SNDK: 76.78 (+1.59), REGN: 518.53 (+3.86), AVGO: 120.50 (+0.61), CRM: 75.83 (-1.70)
Futures Flat; Investors Wary Ahead of China Data
at The Street - Sun Oct 18, 6:37PM CDT
China is expected to post its weakest quarterly economic growth since the global financial crisis.
KMI: 31.42 (-0.51), CCI: 83.13 (-0.04), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), AMT: 96.06 (-0.85), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), DBD: 35.06 (-0.97), AMZN: 555.77 (-5.11), FITB: 18.28 (-0.55), SBAC: 111.14 (-1.02), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38)
Futures Dip Slightly After China GDP Barely Beats
at The Street - Sun Oct 18, 9:42AM CDT
China posted its weakest quarterly economic growth since the global financial crisis.
KMI: 31.42 (-0.51), CCI: 83.13 (-0.04), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), AMT: 96.06 (-0.85), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), DBD: 35.06 (-0.97), AMZN: 555.77 (-5.11), FITB: 18.28 (-0.55), SBAC: 111.14 (-1.02), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38)
'Fast Money' Recap: China Could Have Big Role in US Rally's Future
at The Street - Sat Oct 17, 4:00AM CDT
The trading panel discussed their stock picks ahead of earnings and whether Steve Ballmer is doing the right thing investing in Twitter.
BIIB: 276.34 (+10.53), AMZN: 555.77 (-5.11), CMG: 665.67 (-39.96), MCD: 102.54 (-1.30), LLY: 77.01 (-0.78), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), TWTR: 29.30 (-1.61), MSFT: 47.20 (-0.57), BA: 141.19 (+2.31), YUM: 73.56 (+0.53)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 16, 7:13PM CDT
There are a slew of earnings reports expected next week. Cramer's advice? Stop, listen and learn.
KMI: 31.42 (-0.51), MMM: 149.82 (+0.71), VRX: 118.61 (-28.13), UTX: 97.97 (+2.35), KMB: 118.09 (+0.87), PEP: 100.25 (-0.02), NVGS: 14.06 (-0.85), ETP: 45.53 (-1.41), IBM: 140.92 (+0.28), VAC: 63.04 (-1.45), CMG: 665.67 (-39.96), NAT: 16.39 (+0.10), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MSFT: 47.20 (-0.57), BHI: 54.41 (+1.24), AMZN: 555.77 (-5.11), FEYE: 28.76 (-1.53), HAL: 38.40 (+0.72), VFC: 72.64 (-0.61), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38), EPD: 27.13 (-0.77)
IBM, Yahoo!, Chipotle and McDonald's Part of Heavy Earnings Slate
at The Street - Fri Oct 16, 5:19PM CDT
Also reporting this week are Verizon, United Technologies and General Motors, among many others.
KMI: 31.42 (-0.51), MMM: 149.82 (+0.71), LMT: 211.56 (+2.83), VMW: 55.42 (-13.34), UTX: 97.97 (+2.35), LVS: 46.84 (-0.48), YHOO: 31.12 (-1.71), T: 33.60 (-0.15), EBAY: 24.21 (-0.21), IBM: 140.92 (+0.28), CMG: 665.67 (-39.96), AAL: 44.31 (-0.48), GOOGL: 671.80 (-8.20), EMC: 25.77 (-1.72), SIX: 51.19 (+0.11), MSFT: 47.20 (-0.57), UNP: 93.41 (-0.33), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), AXP: 76.51 (-0.44), CS: 24.98 (-0.98), LLY: 77.01 (-0.78), BA: 141.19 (+2.31), MS: 31.48 (-0.77), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), PG: 73.59 (-0.84), VZ: 44.86 (-0.38), DOW: 47.48 (-0.21)
